KR100843053B1 - 중추 신경계 질환의 치료를 위한 5-하이드록시트립트아민수용체(5-ｈｔ)의 조절제로서1-벤질-5-피페라진-1-일-3,4-다이하이드로-1ｈ-퀴나졸린-2-온 유도체 및 각각의1ｈ-벤조(1,2,6)티아다이아진-2,2-다이옥사이드 및1,4-다이하이드로-벤조(ｄ)(1,3)옥사진-2-온 유도체 - Google Patents
중추 신경계 질환의 치료를 위한 5-하이드록시트립트아민수용체(5-ｈｔ)의 조절제로서1-벤질-5-피페라진-1-일-3,4-다이하이드로-1ｈ-퀴나졸린-2-온 유도체 및 각각의1ｈ-벤조(1,2,6)티아다이아진-2,2-다이옥사이드 및1,4-다이하이드로-벤조(ｄ)(1,3)옥사진-2-온 유도체 Download PDFInfo
- Publication number
- KR100843053B1 KR100843053B1 KR1020067014320A KR20067014320A KR100843053B1 KR 100843053 B1 KR100843053 B1 KR 100843053B1 KR 1020067014320 A KR1020067014320 A KR 1020067014320A KR 20067014320 A KR20067014320 A KR 20067014320A KR 100843053 B1 KR100843053 B1 KR 100843053B1
- Authority
- KR
- South Korea
- Prior art keywords
- dihydro
- benzyl
- piperazin
- quinazolin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)(C)OC(N(CC1)CCN1c1cccc([N+](*)[O-])c1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1cccc([N+](*)[O-])c1C#N)=O 0.000 description 3
- JRBRVPRCINZXEB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c(cccc1N)c1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c(cccc1N)c1C#N)=O JRBRVPRCINZXEB-UHFFFAOYSA-N 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N CC(C)(C)OC(N1CCNCC1)=O Chemical compound CC(C)(C)OC(N1CCNCC1)=O CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- OOVSYCAWVAZGPC-UHFFFAOYSA-N CN(CC1)CCN1c(c(F)ccc1F)c1C#N Chemical compound CN(CC1)CCN1c(c(F)ccc1F)c1C#N OOVSYCAWVAZGPC-UHFFFAOYSA-N 0.000 description 2
- MMEFFVXNWLLTCC-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc(c(N)ccc1)c1[Br]=C)=O Chemical compound CC(C)(C)OC(N(C)Cc(c(N)ccc1)c1[Br]=C)=O MMEFFVXNWLLTCC-UHFFFAOYSA-N 0.000 description 1
- RDJSMZOMBDWYRJ-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc(c([N+]([O-])=O)ccc1)c1Br)=O Chemical compound CC(C)(C)OC(N(C)Cc(c([N+]([O-])=O)ccc1)c1Br)=O RDJSMZOMBDWYRJ-UHFFFAOYSA-N 0.000 description 1
- MIUPDFJHPJHLAI-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c(c(C#N)c(cc1)NCc2ccccc2)c1F)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c(c(C#N)c(cc1)NCc2ccccc2)c1F)=O MIUPDFJHPJHLAI-UHFFFAOYSA-N 0.000 description 1
- SXCYZPBKFOMTJB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c(c(CN)c(cc1)NCc2ccccc2)c1F)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c(c(CN)c(cc1)NCc2ccccc2)c1F)=O SXCYZPBKFOMTJB-UHFFFAOYSA-N 0.000 description 1
- SOHKJZAWOLIKCI-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c(c(CN1)c(cc2)N(Cc3ccccc3)C1=O)c2F)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c(c(CN1)c(cc2)N(Cc3ccccc3)C1=O)c2F)=O SOHKJZAWOLIKCI-UHFFFAOYSA-N 0.000 description 1
- XKXYIEJKQOOKRM-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c(cccc1[N+]([O-])=O)c1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c(cccc1[N+]([O-])=O)c1C#N)=O XKXYIEJKQOOKRM-UHFFFAOYSA-N 0.000 description 1
- QWZIXSCCYFFUSP-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1cccc(NC(c(cc2)ccc2F)=O)c1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1cccc(NC(c(cc2)ccc2F)=O)c1C#N)=O QWZIXSCCYFFUSP-UHFFFAOYSA-N 0.000 description 1
- YGGINVVRRYHVKY-UHFFFAOYSA-N CC1C=CC(CN(c(cc2)c(CN3)c(N4CCNCC4)c2F)C3=O)=CC1 Chemical compound CC1C=CC(CN(c(cc2)c(CN3)c(N4CCNCC4)c2F)C3=O)=CC1 YGGINVVRRYHVKY-UHFFFAOYSA-N 0.000 description 1
- HFFZIZHXDRWHBU-UHFFFAOYSA-N CN(CC1)CCN1c1cccc(NCc(cc2)ccc2F)c1CN Chemical compound CN(CC1)CCN1c1cccc(NCc(cc2)ccc2F)c1CN HFFZIZHXDRWHBU-UHFFFAOYSA-N 0.000 description 1
- GJRIBNCYNPSNJD-UHFFFAOYSA-N CN(Cc(c(Br)ccc1)c1N1Cc2cccc(F)c2)C1O Chemical compound CN(Cc(c(Br)ccc1)c1N1Cc2cccc(F)c2)C1O GJRIBNCYNPSNJD-UHFFFAOYSA-N 0.000 description 1
- PJDFWQSESQKQNK-UHFFFAOYSA-N CN(Cc(c(N1CCNCC1)ccc1)c1N1Cc2cc(F)ccc2)C1=O Chemical compound CN(Cc(c(N1CCNCC1)ccc1)c1N1Cc2cc(F)ccc2)C1=O PJDFWQSESQKQNK-UHFFFAOYSA-N 0.000 description 1
- XTRDKALNCIHHNI-UHFFFAOYSA-N Cc(c([N+]([O-])=O)ccc1)c1[N+]([O-])=O Chemical compound Cc(c([N+]([O-])=O)ccc1)c1[N+]([O-])=O XTRDKALNCIHHNI-UHFFFAOYSA-N 0.000 description 1
- YWTXHALVWAISPR-UHFFFAOYSA-N N#Cc(c(F)c(cc1)F)c1F Chemical compound N#Cc(c(F)c(cc1)F)c1F YWTXHALVWAISPR-UHFFFAOYSA-N 0.000 description 1
- SNJNVLHIFSWKBF-UHFFFAOYSA-N N#Cc(c([N+]([O-])=O)cc(F)c1)c1[N+]([O-])=O Chemical compound N#Cc(c([N+]([O-])=O)cc(F)c1)c1[N+]([O-])=O SNJNVLHIFSWKBF-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N NCc1ccccc1 Chemical compound NCc1ccccc1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N O=C(c(cc1)ccc1F)Cl Chemical compound O=C(c(cc1)ccc1F)Cl CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- JSXJYGLDJJHAPT-UHFFFAOYSA-N [O-][N+](c1cc(F)cc([N+]([O-])=O)c1Cl)=O Chemical compound [O-][N+](c1cc(F)cc([N+]([O-])=O)c1Cl)=O JSXJYGLDJJHAPT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53708004P | 2004-01-16 | 2004-01-16 | |
| US60/537,080 | 2004-01-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20060126720A KR20060126720A (ko) | 2006-12-08 |
| KR100843053B1 true KR100843053B1 (ko) | 2008-07-01 |
Family
ID=34794441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067014320A Expired - Fee Related KR100843053B1 (ko) | 2004-01-16 | 2005-01-07 | 중추 신경계 질환의 치료를 위한 5-하이드록시트립트아민수용체(5-ｈｔ)의 조절제로서1-벤질-5-피페라진-1-일-3,4-다이하이드로-1ｈ-퀴나졸린-2-온 유도체 및 각각의1ｈ-벤조(1,2,6)티아다이아진-2,2-다이옥사이드 및1,4-다이하이드로-벤조(ｄ)(1,3)옥사진-2-온 유도체 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7196087B2 (enExample) |
| EP (1) | EP1708713B1 (enExample) |
| JP (1) | JP4533391B2 (enExample) |
| KR (1) | KR100843053B1 (enExample) |
| CN (1) | CN1909909B (enExample) |
| AR (1) | AR047958A1 (enExample) |
| AT (1) | ATE388712T1 (enExample) |
| AU (1) | AU2005205016B2 (enExample) |
| BR (1) | BRPI0506909A (enExample) |
| CA (1) | CA2552681A1 (enExample) |
| CO (1) | CO5700763A2 (enExample) |
| DE (1) | DE602005005298T2 (enExample) |
| ES (1) | ES2302174T3 (enExample) |
| IL (1) | IL176631A0 (enExample) |
| NO (1) | NO20062791L (enExample) |
| RU (1) | RU2006129464A (enExample) |
| TW (1) | TW200530222A (enExample) |
| WO (1) | WO2005067933A1 (enExample) |
| ZA (1) | ZA200605434B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102114244A (zh) * | 2004-09-30 | 2011-07-06 | 弗·哈夫曼-拉罗切有限公司 | 治疗认知障碍的组合物和方法 |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| US7576094B2 (en) * | 2004-12-13 | 2009-08-18 | Eli Lilly And Company | Spiro derivatives as lipoxygenase inhibitors |
| BRPI0613430A2 (pt) * | 2005-07-13 | 2011-01-11 | Hoffmann La Roche | compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica |
| KR100817538B1 (ko) * | 2006-07-05 | 2008-03-27 | 한국화학연구원 | 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물 |
| KR20090107994A (ko) * | 2006-09-11 | 2009-10-14 | 엔.브이.오가논 | 퀴나졸리논 및 이소퀴놀리논 아세트아미드 유도체 |
| US7718652B2 (en) | 2006-12-12 | 2010-05-18 | Wyeth Llc | Substituted benzothiadiazinedioxide derivatives and methods of their use |
| CA2728376C (en) * | 2008-06-20 | 2015-05-12 | Rottapharm S.P.A. | 6-1h-imidazo-quinazoline and quinolines derivatives/mao inhibitors for treating depression |
| EP2328881A1 (en) * | 2008-09-08 | 2011-06-08 | F. Hoffmann-La Roche AG | 5-substituted benzoxazines |
| AU2011255169A1 (en) | 2010-05-21 | 2013-01-17 | Shanghai Institute Of Pharmaceutical Industry | Fused quinazoline derivatives and uses thereof |
| IL291029B2 (en) * | 2016-11-15 | 2024-06-01 | Univ Temple | New modulators of 5-hydroxytryptamine receptor 7 and a method of using them |
| KR20220012244A (ko) | 2019-04-29 | 2022-02-03 | 솔렌트 테라퓨틱스, 엘엘씨 | Mrgx2의 억제제로서의 3-아미노-4h-벤조[e][1,2,4]티아디아진 1,1-디옥사이드 유도체 |
| CN114929688B (zh) * | 2019-10-21 | 2024-11-01 | 阿莱瑞恩公司 | 作为H1和5-HT2A-受体调节剂、用于治疗睡眠障碍的3-(4-(11H-二苯并[b,e][1,4]吖庚英-6-基)哌嗪-1-基)-和3-(4-(二苯并[b,f][1,4]氧杂吖庚英/硫杂吖庚英/二吖庚英-11-基)哌嗪-1-基)-丙酸衍生物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999037643A1 (en) * | 1998-01-26 | 1999-07-29 | Yamanouchi Pharmaceutical Co., Ltd. | Novel benzene-fused heterocyclic derivatives or salts thereof |
| WO2003068772A1 (en) * | 2002-02-18 | 2003-08-21 | Glaxo Group Limited | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy |
| WO2003095434A1 (en) * | 2002-05-13 | 2003-11-20 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642791A (en) * | 1969-08-13 | 1972-02-15 | Sandoz Ag | Morpholino-1-substituted-2(1h)-quinazolinones |
| JPS5271483A (en) * | 1975-12-11 | 1977-06-14 | Sumitomo Chem Co Ltd | Synthesis of 2(1h)-quinazolinone derivatives |
| CN1015459B (zh) * | 1985-06-06 | 1992-02-12 | 田边制药株式会社 | 喹唑啉酮化合物的制备方法 |
| GR1000821B (el) * | 1988-11-22 | 1993-01-25 | Tanabe Seiyaku Co | Μεθοδος παραγωγης παραγωγων κιναζολινονης. |
| WO1998018781A2 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
| AU6423298A (en) | 1997-03-26 | 1998-10-20 | Sumitomo Pharmaceuticals Company, Limited | 4-arylmethylene-1,4-dihydro-2h-azine derivatives |
| PT1028950E (pt) | 1997-10-28 | 2003-09-30 | Warner Lambert Co | Quinazolina-2,4-dionas 7-substituidas uteis como agentes antibacterianos |
| ATE286883T1 (de) * | 1999-11-05 | 2005-01-15 | Smithkline Beecham Plc | Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität |
| JP2003517471A (ja) | 1999-11-23 | 2003-05-27 | スミスクライン・ビーチャム・コーポレイション | ３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オンおよびそのＣＳＢＰ／ｐ３８キナーゼ阻害剤としての使用 |
| WO2001044228A2 (fr) | 1999-12-14 | 2001-06-21 | Sanofi-Synthelabo | Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique |
| EP1345603A4 (en) * | 2000-12-20 | 2004-09-08 | Merck & Co Inc | (HALO-BENZO-CARBONYL) HETEROCYCLO-CONDENSED PHENYL-P38-KINASE INHIBITING AGENTS |
| US6998408B2 (en) * | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| CA2450245A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
-
2005
- 2005-01-07 EP EP05700747A patent/EP1708713B1/en not_active Expired - Lifetime
- 2005-01-07 AU AU2005205016A patent/AU2005205016B2/en not_active Ceased
- 2005-01-07 WO PCT/EP2005/000095 patent/WO2005067933A1/en not_active Ceased
- 2005-01-07 DE DE602005005298T patent/DE602005005298T2/de not_active Expired - Lifetime
- 2005-01-07 KR KR1020067014320A patent/KR100843053B1/ko not_active Expired - Fee Related
- 2005-01-07 CA CA002552681A patent/CA2552681A1/en not_active Abandoned
- 2005-01-07 ES ES05700747T patent/ES2302174T3/es not_active Expired - Lifetime
- 2005-01-07 CN CN2005800026123A patent/CN1909909B/zh not_active Expired - Fee Related
- 2005-01-07 BR BRPI0506909-2A patent/BRPI0506909A/pt not_active IP Right Cessation
- 2005-01-07 RU RU2006129464/04A patent/RU2006129464A/ru unknown
- 2005-01-07 JP JP2006548231A patent/JP4533391B2/ja not_active Expired - Fee Related
- 2005-01-07 AT AT05700747T patent/ATE388712T1/de active
- 2005-01-13 AR ARP050100106A patent/AR047958A1/es not_active Application Discontinuation
- 2005-01-13 TW TW094101029A patent/TW200530222A/zh unknown
- 2005-01-14 US US11/035,506 patent/US7196087B2/en not_active Expired - Fee Related
-
2006
- 2006-06-15 NO NO20062791A patent/NO20062791L/no not_active Application Discontinuation
- 2006-06-29 IL IL176631A patent/IL176631A0/en unknown
- 2006-06-30 ZA ZA200605434A patent/ZA200605434B/en unknown
- 2006-07-13 CO CO06068258A patent/CO5700763A2/es not_active Application Discontinuation
-
2007
- 2007-02-07 US US11/703,424 patent/US7365063B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999037643A1 (en) * | 1998-01-26 | 1999-07-29 | Yamanouchi Pharmaceutical Co., Ltd. | Novel benzene-fused heterocyclic derivatives or salts thereof |
| WO2003068772A1 (en) * | 2002-02-18 | 2003-08-21 | Glaxo Group Limited | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy |
| WO2003095434A1 (en) * | 2002-05-13 | 2003-11-20 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1708713B1 (en) | 2008-03-12 |
| AU2005205016A1 (en) | 2005-07-28 |
| US7196087B2 (en) | 2007-03-27 |
| AU2005205016B2 (en) | 2010-07-15 |
| CN1909909B (zh) | 2010-12-15 |
| BRPI0506909A (pt) | 2007-05-29 |
| DE602005005298T2 (de) | 2009-03-12 |
| ATE388712T1 (de) | 2008-03-15 |
| ES2302174T3 (es) | 2008-07-01 |
| IL176631A0 (en) | 2006-10-31 |
| JP4533391B2 (ja) | 2010-09-01 |
| KR20060126720A (ko) | 2006-12-08 |
| EP1708713A1 (en) | 2006-10-11 |
| CO5700763A2 (es) | 2006-11-30 |
| CA2552681A1 (en) | 2005-07-28 |
| RU2006129464A (ru) | 2008-02-27 |
| US20050165001A1 (en) | 2005-07-28 |
| ZA200605434B (en) | 2008-02-27 |
| AR047958A1 (es) | 2006-03-15 |
| TW200530222A (en) | 2005-09-16 |
| DE602005005298D1 (de) | 2008-04-24 |
| US20070149510A1 (en) | 2007-06-28 |
| WO2005067933A1 (en) | 2005-07-28 |
| CN1909909A (zh) | 2007-02-07 |
| NO20062791L (no) | 2006-08-01 |
| US7365063B2 (en) | 2008-04-29 |
| JP2007517826A (ja) | 2007-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7365063B2 (en) | Quinazolinone and benzoxazinone derivatives and uses thereof | |
| AU2003293653B2 (en) | Substituted benzoxazinones and uses thereof | |
| KR100827915B1 (ko) | 벤즈옥사진 유도체 및 그의 용도 | |
| KR100691090B1 (ko) | 퀴놀리논/벤즈옥사지논 유도체 및 이들의 용도 | |
| KR20070047844A (ko) | 벤즈옥사진 및 퀴녹살린 유도체 및 용도 | |
| MXPA06007907A (en) | 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system | |
| HK1087114B (en) | Substituted benzoxazinones and uses thereof | |
| HK1087114A1 (zh) | 取代的苯并恶嗪酮及其用途 | |
| MXPA06005840A (en) | Benzoxazine derivatives and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20110626 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20110626 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |